Journal Watch · Frontiers in Immunology · 2026
Imaging predictors of response and outcomes after CAR T-cell therapy in lymphoma: from clinical trials to real-world practice.
By moving beyond descriptive staging toward structured, predictive baseline imaging evaluation, radiologists and lymphoma clinicians may improve pretreatment risk stratification and facilitate more informed therapeutic decision-making in the expanding landscape of CAR T-cell therapy.
TL;DR
By moving beyond descriptive staging toward structured, predictive baseline imaging evaluation, radiologists and lymphoma clinicians may improve pretreatment risk stratification and facilitate more informed therapeutic decision-making in the expanding landscape of CAR T-cell therapy.
Key findings
- Despite a growing body of evidence linking these imaging features to outcomes, clinical adoption has been limited by heterogeneous measurement methodologies, inconsistent definitions, and a lack of prospective validation.
- We propose practical considerations for structured baseline imaging assessment, including a reporting checklist designed to ensure systematic documentation of the imaging features with demonstrated or emerging prognostic relevance.
- By moving beyond descriptive staging toward structured, predictive baseline imaging evaluation, radiologists and lymphoma clinicians may improve pretreatment risk stratification and facilitate more informed therapeutic decision-making in the expanding landscape of CAR T-cell therapy.
What they did
This review examines the role of baseline Fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) features as predictors of response and survival after CAR T-cell therapy in lymphoma. We synthesize the evidence on established imaging predictors, including total metabolic tumor volume, extranodal disease distribution and site-specific organ involvement, and bulky disease, and discuss emerging biomarkers such as body composition metrics.
Full abstract (original)
Background: Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of relapsed or refractory large B-cell lymphoma, with overall response rates in real-world practice broadly comparable to those in pivotal clinical trials. However, progression-free survival is consistently shorter in real-world cohorts, suggesting that baseline disease characteristics may influence long-term outcomes more than initial treatment sensitivity.
What they did: This review examines the role of baseline Fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) features as predictors of response and survival after CAR T-cell therapy in lymphoma. We synthesize the evidence on established imaging predictors, including total metabolic tumor volume, extranodal disease distribution and site-specific organ involvement, and bulky disease, and discuss emerging biomarkers such as body composition metrics.
Results & conclusions: Despite a growing body of evidence linking these imaging features to outcomes, clinical adoption has been limited by heterogeneous measurement methodologies, inconsistent definitions, and a lack of prospective validation. We propose practical considerations for structured baseline imaging assessment, including a reporting checklist designed to ensure systematic documentation of the imaging features with demonstrated or emerging prognostic relevance. By moving beyond descriptive staging toward structured, predictive baseline imaging evaluation, radiologists and lymphoma clinicians may improve pretreatment risk stratification and facilitate more informed therapeutic decision-making in the expanding landscape of CAR T-cell therapy.
Abstract © the authors / Frontiers in Immunology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.3389/fimmu.2026.1846426 · PubMed 42528814.
Why it matters for pharma & biotech
- Directly relevant to teams in cell therapy (CAR-T / engineered cells) — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
- As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
- For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.
Modalities & themes detected: cell therapy (CAR-T / engineered cells)
Limitations & what to check in the full text
- This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
- The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.
Frequently asked questions
What did this Frontiers in Immunology study find?
By moving beyond descriptive staging toward structured, predictive baseline imaging evaluation, radiologists and lymphoma clinicians may improve pretreatment risk stratification and facilitate more informed therapeutic decision-making in the expanding landscape of CAR T-cell therapy.
What type of study is this?
It is a cohort / observational clinical study, published in Frontiers in Immunology in 2026. This review examines the role of baseline Fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) features as predictors of response and survival after CAR T-cell therapy in lymphoma.
Where can I read the original paper?
The original is at the publisher via DOI 10.3389/fimmu.2026.1846426. PubMed ID: 42528814. BioStudioAI reproduces the abstract for discussion and links to the source.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/imaging-predictors-of-response-and-outcomes-after-car-t-cell-therapy-in-846426/
Reading papers is step one. Analysing the data is the work.
BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.
Open BioStudioAI More guides